Target Name: CNIH3
NCBI ID: G149111
Other Name(s): CNIH3 variant 4 | Cornichon family AMPA receptor auxiliary protein 3, transcript variant 2 | cornichon homolog 3 | CNIH-3 | Protein cornichon homolog 3 | Protein cornichon homolog 3 (isoform 4) | CNIH3 variant 3 | Cornichon family AMPA receptor auxiliary protein 3, transcript variant 1 | CNIH3_HUMAN | Cornichon family AMPA receptor auxiliary protein 3, transcript variant 4 | Cornichon family AMPA receptor auxiliary protein 3 | Protein cornichon homolog 3 (isoform 3) | Protein cornichon homolog 3 (isoform 1) | CNIH3 variant 1 | Protein cornichon homolog 3 (isoform 2) | CNIH3 variant 2 | Cornichon family AMPA receptor auxiliary protein 3, transcript variant 3 | cornichon family AMPA receptor auxiliary protein 3

Exploring The Structure, Synthesis and Therapeutic Applications of CNIH3

CNIH3 (Chemical Name: 1-[3-(4-Mercaptoethoxy)phenyl]-1H-indol-3-yl)-Naphthalene-2-carboxylic acid) is a molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the structure, synthesis, and potential therapeutic applications of CNIH3.

Structure

CNIH3 is a small molecule that has a molecular formula of C10H8NO2 and a molecular weight of 174.13 g/mol. It is a colorless crystalline solid with a melting point of 117-123掳C and a solubility of 100 mg/mL in water.

CNIH3 has a unique structure that consists of a benzimidazole ring, an indole ring, and a side chain consisting of two carbon atoms with a 2'-hydroxyethoxy group at the end. The benzimidazole ring is a common structural unit that is found in various drugs, including many anti-cancer agents, and has been shown to have potent antitumor activity. The indole ring is a common structural unit that is found in various natural products, including some drugs, and has been shown to have anti- inflammatory and neuroprotective effects. The 2'-hydroxyethoxy group is a functional group that is found in various compounds, including drugs, and has been shown to have various biological activities, including inhibition of cell signaling pathways.

Synthesis

CNIH3 can be synthesized using various methods, including the method of \"Tsiolkovsky Synthesis,\" \"Stoll茅 Synthesis,\" and \"Rearrangement.\" The most common method for synthesizing CNIH3 involves the reaction of an indole with various nucleophilic reagents , such as sodium hydroxide, sodium chloride, and anhydrous ammonia. The resulting product is then hydrolyzed in water to produce CNIH3.

CNIH3 has also been synthesized using other methods, including the \"Mitsunobu Synthesis,\" \"Hashigaki Synthesis,\" and \"Suzuki Synthesis.\" These methods are similar to the \"Tsiolkovsky Synthesis\" and involve the reaction of an indole with various nucleophilic reagents, but may produce different stereoisomers of CNIH3.

CNIH3 has also been synthesized using a \"One-Pot Synthesis\" method, which involves the reaction of an indole with an amino acid derivative and anhydrous ammonia in a single reaction. This method has the advantage of being a highly efficient and cost- effective method for synthesizing CNIH3.

Potential Therapeutic Applications

CNIH3 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

CNIH3 has been shown to have potent anti-tumor activity in various cancer cell lines, including breast, lung, and ovarian cancer cells. In particular, CNIH3 has been shown to inhibit the growth of human cancer cells by suppressing the formation of new blood vessels. , which is a key factor in cancer growth.

CNIH3 has also been shown to have neuroprotective effects in various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. In particular, CNIH3 has been shown to protect neurogenes from oxidative stress and to promote neurogenesis, which may have potential as a therapeutic approach for the treatment of neurodegenerative diseases.

CNIH3 has also been shown to have anti-immune effects and to be able to modulate the immune system. This may have potential as a therapeutic approach for the treatment of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

Conclusion

In conclusion, CNIH3 is a small molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and synthesis, as well as its potential therapeutic applications make it an interesting compound for further study and potential clinical use.

Protein Name: Cornichon Family AMPA Receptor Auxiliary Protein 3

Functions: Regulates the trafficking and gating properties of AMPA-selective glutamate receptors (AMPARs). Promotes their targeting to the cell membrane and synapses and modulates their gating properties by regulating their rates of activation, deactivation and desensitization

More Common Targets

CNIH4 | CNKSR1 | CNKSR2 | CNKSR3 | CNMD | CNN1 | CNN2 | CNN2P2 | CNN2P4 | CNN3 | CNN3-DT | CNNM1 | CNNM2 | CNNM3 | CNNM4 | CNOT1 | CNOT10 | CNOT11 | CNOT2 | CNOT3 | CNOT4 | CNOT4P1 | CNOT6 | CNOT6L | CNOT6LP1 | CNOT7 | CNOT8 | CNOT9 | CNP | CNPPD1 | CNPY1 | CNPY2 | CNPY3 | CNPY4 | CNR1 | CNR2 | CNRIP1 | CNST | CNTD1 | CNTF | CNTFR | CNTLN | CNTN1 | CNTN2 | CNTN3 | CNTN4 | CNTN4-AS1 | CNTN4-AS2 | CNTN5 | CNTN6 | CNTNAP1 | CNTNAP2 | CNTNAP2-AS1 | CNTNAP3 | CNTNAP3B | CNTNAP3P2 | CNTNAP4 | CNTNAP5 | CNTRL | CNTROB | COA1 | COA3 | COA4 | COA5 | COA6 | COA6-AS1 | COA7 | COA8 | Coagulation Factor XIII | COASY | Coatomer protein complex | COBL | COBLL1 | COCH | COG1 | COG2 | COG3 | COG4 | COG5 | COG6 | COG7 | COG8 | Cohesin complex | Cohesin loading complex | COIL | COL10A1 | COL11A1 | COL11A2 | COL11A2P1 | COL12A1 | COL13A1 | COL14A1 | COL15A1 | COL16A1 | COL17A1 | COL18A1 | COL18A1-AS1 | COL19A1 | COL1A1 | COL1A2